.gif)
Soligenix Inc announced that the Chinese Patent Office intends to grant the patent entitled “Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity.” The newly issued patent claims composition of matter of dusquetide (research name: SGX94) and related analogs.
Dusquetide recently demonstrated positive results in a Phase 2 oral mucositis clinical trial. China now becomes the most recent jurisdiction to grant patent coverage over the composition of matter of dusquetide. Similar claims have been granted in the United States, Australia, Israel, Japan, Mexico, New Zealand, Republic of Korea, Russian Federation, Singapore, South Africa and Taiwan. Furthermore, Soligenix is expecting to be granted similar protections in other important jurisdictions, including Europe, in the very near term.
Soligenix recently reported positive Phase 2 results with SGX942, its drug product containing dusquetide, in the treatment of oral mucositis in head and neck cancer patients. SGX942 at a dose of 1.5 mg/kg successfully reduced the median duration of severe oral mucositis by 50% in all patients and by 67% in patients receiving the most aggressive chemoradiation therapy for treatment of their head and neck cancer. In addition to the oral mucositis findings, an increased incidence of “complete response” of tumor at the one month follow-up visit was observed (47% in placebo versus 63% in SGX942 at 1.5 mg/kg). Decreases in infection rate were also observed with SGX942 treatment.
The new patents correspond to US patent 8,124,721, granted on February 28, 2012, that primarily included composition of matter claims and therapeutic use claims in infectious disease for dusquetide.
